APA

Shah P., Glueck C. J., Goldenberg N., Min S., Mahida C., Schlam I., Rothschild M., Huda A. & Wang P. (20170612). Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study. : Lipids in health and disease.

Chicago

Shah Parth, Glueck Charles J, Goldenberg Naila, Min Sarah, Mahida Chris, Schlam Ilana, Rothschild Matan, Huda Ali and Wang Ping. 20170612. Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study. : Lipids in health and disease.

Harvard

Shah P., Glueck C. J., Goldenberg N., Min S., Mahida C., Schlam I., Rothschild M., Huda A. and Wang P. (20170612). Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study. : Lipids in health and disease.

MLA

Shah Parth, Glueck Charles J, Goldenberg Naila, Min Sarah, Mahida Chris, Schlam Ilana, Rothschild Matan, Huda Ali and Wang Ping. Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study. : Lipids in health and disease. 20170612.